Taken together, these studies verify that expression of MYCN protein in neuroblastoma cells is a major determinant of GSK3203591 sensitivity, and further validate a MYCN-PRMT5 axis crucial to survival and proliferation of neuroblastoma as suggested previously using PRMT5 knockdowns [5]. The gene discussed is PRMT5; the disease is neuroblastoma.